Dual NLRP3 and IL-6 trans-signaling blockade reverses immunosenescence by disrupting a mitochondrial ROS–STAT3 metabolic loop
Hypothesis
Combined pharmacological inhibition of the NLRP3 inflammasome (using MCC950) and IL-6 trans-signaling (using sgp130Fc) will synergistically restore thymic output and reverse T‑cell metabolic reprogramming in aged humans by breaking a self‑reinforcing NLRP3‑mitochondria‑ROS‑IL‑6‑STAT3 circuit.
Rationale
- NLRP3 activation in macrophages drives mitochondrial dysfunction and ROS production, which stabilizes HIF‑1α and amplifies IL-6 transcription [[https://pmc.ncbi.nlm.nih.gov/articles/PMC12328749/]].
- IL-6 trans-signaling engages soluble IL‑6R/gp130 on naïve T cells, activating STAT3 and upregulating Glut1‑dependent glycolysis and glutaminolysis, a state that further fuels NLRP3 via succinate accumulation [[https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1568514/full]].
- Genetic NLRP3/ASC deletion rescues thymic progenitors in mice, while LDH inhibition (FX11) selectively blocks Th17 differentiation, indicating metabolic control of inflammasome activity [[https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2025.1688060/full]], [[https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1568514/full]].
Novel Mechanistic Insight
We posit that mitochondrial ROS not only activates NLRP3 but also oxidizes specific cysteine residues on the IL‑6 receptor complex, enhancing its shedding and increasing soluble IL‑6R availability. This creates a feed‑forward loop where ROS‑driven NLRP3 activity elevates IL‑6 trans‑signaling, which in turn augments mitochondrial ROS via STAT3‑mediated metabolic rewiring. Simultaneous blockade of NLRP3 (preventing ROS burst) and IL‑6 trans‑signaling (blocking STAT3 activation) should therefore collapse the loop, reduce oxidative stress, and allow metabolic reset toward oxidative phosphorylation in T cells.
Testable Predictions
- In peripheral blood mononuclear cells from donors >65 years, combined MCC950 + sgp130Fc will reduce mitochondrial ROS (MitoSOX) more than either agent alone.
- The combination will decrease phospho‑STAT3 (Y705) and HIF‑1α levels in CD4⁺ T cells, shifting glycolysis/OXPHOS ratio toward baseline youthful values.
- Thymic output, quantified by sjTREC frequency, will increase significantly after 12 weeks of treatment only in the dual‑inhibition arm.
- Senescence biomarkers (p16^INK4a, SASP IL‑1β, IL‑6) in sorted CD8⁺ CD28⁻ T cells will show additive suppression.
Proposed Experimental Design
- Population: 120 healthy adults aged 65‑80, stratified by sex and baseline inflammasome activity.
- Arms: (i) placebo, (ii) MCC950 monotherapy, (iii) sgp130Fc monotherapy, (iv) MCC950 + sgp130Fc.
- Duration: 12 weeks dosing, with follow‑up at 24 weeks to assess durability.
- Endpoints: Primary – change in sjTREC; Secondary – mitochondrial ROS, p‑STAT3, glycolysis (ECAR), OXPHOS (OCR), cytokine SASP profile, thymic ultrasound echogenicity.
- Statistical Plan: Two‑way ANOVA for interaction effects; power = 0.8 to detect 20 % sjTREC increase with α = 0.05.
Falsifiability
If dual treatment fails to produce a statistically significant greater reduction in mitochondrial ROS or increase in sjTREC compared with the best single agent, the hypothesis that NLRP3‑IL‑6 trans‑signaling crosstalk forms a necessary metabolic loop driving immunosenescence will be refuted. Conversely, a clear synergistic effect would support the model and justify further mechanistic studies targeting the ROS‑STAT3 axis in aging immunity.